Relationship Between Body Composition and Hormone Sensitivity for Androgen Deprivation Therapy in Patients with Metastatic Prostate Cancer

Overview

Journal Prostate Int

Date 2020 Apr 8

PMID 32257974

Citations 9

Authors

Eiji Kashiwagi

Masaki Shiota

Hiroyuki Masaoka

Kenjiro Imada

Keisuke Monji

Ario Takeuchi

Junichi Inokuchi

Katsunori Tatsugami

Masatoshi Eto

Affiliations

Soon will be listed here.

Abstract

Background: To evaluate the relationship between body composition and the oncological outcome of androgen deprivation therapy (ADT), we investigated whether body composition features including the psoas muscle may be predictive factors of ADT.

Methods: This study enrolled patients with hormone-naïve metastatic prostate cancer who were treated with primary ADT from April 1996 to November 2013 at Kyushu University Hospital and who underwent a computed tomography scan before primary ADT for calculating body fat percentage, psoas muscle ratio (psoas muscle, cm/height, cm), and body mass index.

Results: Of the 178 patients enrolled, 60 patients died during follow-up. Median follow-up was 32 months, and progression-free survival and overall survival (OS) were 28 and 80 months, respectively. Multivariate analysis revealed that the psoas muscle ratio was correlated with OS (hazard ratio: 0.448; 95% confidence interval = 0.206-0.922; = 0.028).

Conclusions: This study demonstrated that higher psoas muscle ratio predicts longer OS among patients with nonlocalized prostate cancer treated with primary ADT.

Citing Articles

The Association Between Body Composition, Overall Survival, Treatment Decisions, and Patient-Reported Outcomes in Metastatic Non-Small-Cell Lung Cancer.

Coletta A, Lee H, Puri S, Culleton S, Covington M, Yap J Cancer Med. 2025; 14(1):e70534.

PMID: 39764691 PMC: 11705441. DOI: 10.1002/cam4.70534.

Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes.

Leong D, Fradet V, Niazi T, Selvanayagam J, Sabbagh R, Higano C JACC CardioOncol. 2024; 6(5):761-771.

PMID: 39479325 PMC: 11520207. DOI: 10.1016/j.jaccao.2024.07.011.

Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial.

Coletta A, Simon L, Maslana K, Taylor S, Larson K, Hansen P BMC Cancer. 2024; 24(1):493.

PMID: 38637770 PMC: 11025211. DOI: 10.1186/s12885-024-12260-3.

Psoas mass index at the level of the third lumbar vertebra on computed tomography is a prognostic predictor for metastatic castration-sensitive prostate cancer.

Owa S, Sasaki T, Ikadai R, Tabata Y, Takeuchi Y, Nishikawa T Int J Clin Oncol. 2024; 29(6):840-846.

PMID: 38587577 DOI: 10.1007/s10147-024-02514-2.

Association between adiposity after diagnosis of prostate cancer and mortality: systematic review and meta-analysis.

Cariolou M, Markozannes G, Becerra-Tomas N, Vieira R, Balducci K, Aune D BMJ Med. 2023; 2(1):e000339.

PMID: 37841967 PMC: 10568122. DOI: 10.1136/bmjmed-2022-000339.

References

Shiota M, Takeuchi A, Sugimoto M, Kashiwagi E, Dejima T, Kiyoshima K . Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer. Anticancer Res. 2015; 35(12):6925-32. View

Galvao D, Taaffe D, Spry N, Newton R . Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer. Prostate Cancer Prostatic Dis. 2007; 10(4):340-6. DOI: 10.1038/sj.pcan.4500975. View

Isbarn H, Boccon-Gibod L, Carroll P, Montorsi F, Schulman C, Smith M . Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol. 2008; 55(1):62-75. PMC: 3090670. DOI: 10.1016/j.eururo.2008.10.008. View

Oefelein M, Cornum R . Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol. 2000; 164(3 Pt 1):726-9. DOI: 10.1097/00005392-200009010-00025. View

Bhasin S, Woodhouse L, Casaburi R, Singh A, Bhasin D, Berman N . Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001; 281(6):E1172-81. DOI: 10.1152/ajpendo.2001.281.6.E1172. View

Scher H, Halabi S, Tannock I, Morris M, Sternberg C, Carducci M . Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26(7):1148-59. PMC: 4010133. DOI: 10.1200/JCO.2007.12.4487. View

Smith A, Deal A, Yu H, Boyd B, Matthews J, Wallen E . Sarcopenia as a predictor of complications and survival following radical cystectomy. J Urol. 2014; 191(6):1714-20. DOI: 10.1016/j.juro.2013.12.047. View

Montgomery R, Goldman B, Tangen C, Hussain M, Petrylak D, Page S . Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. J Urol. 2007; 178(5):1946-51. DOI: 10.1016/j.juro.2007.07.026. View

Lane B, Stephenson A, Magi-Galluzzi C, Lakin M, Klein E . Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology. 2008; 72(6):1240-5. DOI: 10.1016/j.urology.2008.06.001. View

10.

Pahor M, Manini T, Cesari M . Sarcopenia: clinical evaluation, biological markers and other evaluation tools. J Nutr Health Aging. 2009; 13(8):724-8. PMC: 4312657. DOI: 10.1007/s12603-009-0204-9. View

11.

Schiffmann J, Karakiewicz P, Rink M, Manka L, Salomon G, Tilki D . Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients. World J Urol. 2018; 36(7):1067-1072. DOI: 10.1007/s00345-018-2240-8. View

12.

Isom-Batz G, Bianco Jr F, Kattan M, Mulhall J, Lilja H, Eastham J . Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol. 2005; 173(6):1935-7. PMC: 1855287. DOI: 10.1097/01.ju.0000158040.33531.e7. View

13.

Ross R, Xie W, Regan M, Pomerantz M, Nakabayashi M, Daskivich T . Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008; 112(6):1247-53. DOI: 10.1002/cncr.23304. View

14.

Versteeg K, Blauwhoff-Buskermolen S, Buffart L, de van der Schueren M, Langius J, Verheul H . Higher Muscle Strength Is Associated with Prolonged Survival in Older Patients with Advanced Cancer. Oncologist. 2017; 23(5):580-585. PMC: 5947445. DOI: 10.1634/theoncologist.2017-0193. View

15.

Keogh J, MacLeod R . Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: a systematic review. J Pain Symptom Manage. 2011; 43(1):96-110. DOI: 10.1016/j.jpainsymman.2011.03.006. View

16.

Huggins C, Hodges C . Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002; 168(1):9-12. DOI: 10.1016/s0022-5347(05)64820-3. View

17.

Englesbe M, Patel S, He K, Lynch R, Schaubel D, Harbaugh C . Sarcopenia and mortality after liver transplantation. J Am Coll Surg. 2010; 211(2):271-8. PMC: 2914324. DOI: 10.1016/j.jamcollsurg.2010.03.039. View

18.

Imamoto T, Suzuki H, Fukasawa S, Shimbo M, Inahara M, Komiya A . Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol. 2005; 47(3):308-12. DOI: 10.1016/j.eururo.2004.11.003. View

19.

Wright M, Chang S, Schatzkin A, Albanes D, Kipnis V, Mouw T . Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer. 2007; 109(4):675-84. DOI: 10.1002/cncr.22443. View

20.

Smith M . Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin Cancer Res. 2007; 13(1):241-5. PMC: 3047403. DOI: 10.1158/1078-0432.CCR-06-2086. View